Adoptive immunotherapy is an active cell-based cancer treatment approach in which a patient’s own immune cells — or those obtained from a donor — are expanded in the laboratory, genetically modified where necessary, and reinfused into the patient. Its fundamental distinction from conventional immunotherapies lies not in broadly stimulating the immune system, but in directly transferring immune cells with high tumor-specific cytotoxic activity.

Historical Background

The foundations of adoptive immunotherapy trace back to the early 1980s. Steven Rosenberg and his team were the first to demonstrate that tumor-infiltrating lymphocytes (TILs) isolated and expanded ex vivo could induce tumor regression. Over the subsequent decades, advances in T cell receptor engineering and then the development of CAR-T cell technology transformed the field profoundly, elevating it to the status of a clinical standard of care in hematological malignancies.

Principal Cell Types

The main cell types employed in adoptive immunotherapy are as follows:

• Tumor-Infiltrating Lymphocytes (TIL): T cells isolated from tumor tissue with intrinsic tumor specificity; durable response rates have been reported in melanoma
• CAR-T Cells (Chimeric Antigen Receptor T Cells): Genetically engineered T cells to which a synthetic receptor recognizing a tumor surface antigen has been added
• TCR-T Cells: Engineered T cells carrying a high-affinity tumor-specific receptor in place of the natural T cell receptor
• NK Cells (Natural Killer Cells): Advantageous in allogeneic applications due to MHC-independent tumor recognition; CAR-NK developments are ongoing
• Regulatory T Cells (Treg): Under investigation for autoimmune diseases and organ transplant tolerance

Mechanism of CAR-T Cell Therapy

As the most advanced and best-characterized branch of adoptive immunotherapy today, the mechanism of CAR-T warrants detailed consideration.

The chimeric antigen receptor comprises four core domains: the extracellular binding domain that recognizes the tumor antigen (typically a single-chain variable fragment, scFv), a hinge region, a transmembrane domain, and intracellular signaling domains (the CD3ζ chain together with co-stimulatory domains such as CD28 or 4-1BB). Antigen binding activates the cell; the activated CAR-T cell secretes cytokines, proliferates, and kills tumor cells via the perforin/granzyme pathway.

Generational differences are most apparent in signaling richness: first-generation constructs contain only CD3ζ, second-generation add one co-stimulatory domain, third-generation carry two co-stimulatory domains, and fourth-generation — termed “TRUCK” cells — are additionally equipped with enhanced cytokine secretion capacity.

Approved Clinical Applications

CAR-T products approved by the FDA and EMA are used in the following indications:

• Axicabtagene ciloleucel (Yescarta): Relapsed/refractory large B-cell lymphoma, follicular lymphoma
• Tisagenlecleucel (Kymriah): Pediatric/young adult ALL, diffuse large B-cell lymphoma
• Lisocabtagene maraleucel (Breyanzi): Relapsed/refractory large B-cell lymphoma
• Idecabtagene vicleucel (Abecma): Relapsed/refractory multiple myeloma (BCMA-targeted)
• Ciltacabtagene autoleucel (Carvykti): Relapsed/refractory multiple myeloma

Manufacturing Process

Autologous CAR-T production is a complex and time-consuming process. T cells are first collected from the patient via leukapheresis; the CAR gene is then introduced into T cells using viral vectors, typically retroviral or lentiviral. Cells are expanded in ex vivo culture, subjected to quality control testing, and prior to reinfusion, the patient undergoes lymphodepletion chemotherapy to prepare a favorable engraftment environment. The entire process may take four to six weeks — a delay that can be clinically problematic in patients with rapidly progressing disease.

Adverse Effects and Toxicity

Adoptive immunotherapy, and CAR-T therapy in particular, carries a distinctive and sometimes life-threatening toxicity profile.

• Cytokine Release Syndrome (CRS): The most frequently encountered serious adverse effect; characterized by fever, hypotension, and hypoxia; ranges from mild to fulminant; treated with tocilizumab
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Confusion, aphasia, tremor, seizures, and cerebral edema; may respond to corticosteroid therapy
• B cell aplasia: An expected on-target effect of CD19-directed therapies; requires intravenous immunoglobulin replacement
• Cytopenias: Prolonged bone marrow suppression arising from lymphodepletion and ongoing inflammation
• Anaphylaxis: An acute reaction requiring particular vigilance with allogeneic products

Current Limitations and Research Directions

The most significant challenge facing the field is the markedly inferior efficacy of CAR-T therapy in solid tumors compared to hematological malignancies. The immunosuppressive tumor microenvironment, immune escape through antigen loss, insufficient CAR-T infiltration into the tumor, and T cell exhaustion are the principal barriers. Research efforts directed at overcoming these obstacles are focused on dual antigen-targeting CAR constructs, allogeneic “off-the-shelf” CAR-T products, combination approaches targeting the tumor microenvironment, and the integration of advanced gene editing tools such as CRISPR-Cas9.

Clinical Significance

Adoptive immunotherapy — and CAR-T cell therapy in particular — is recognized as a paradigm-shifting development in oncology by virtue of its ability to achieve durable complete remission in hematological cancers refractory to standard treatments. Nevertheless, high cost, complex manufacturing logistics, serious toxicity management requirements, and limited accessibility remain the principal obstacles to its widespread adoption.